


1824 South Robertson Blvd.
 Los Angeles, CA 90035-4317
 310/204-6936 • 800/726-0886

www.jarrow.com
 April 18, 2003

FAX NUMBERS

Orders 800/890-8955
 General 310/204-2520
 Administrative 310/204-5132

SECTION 403 (r) (6) NOTIFICATION

Food and Drug Administration
 Center for Food Safety and Applied Nutrition
 Office of Nutritional Products, Labeling, and Dietary Supplements (HFS-810)
 5100 Paint Branch Parkway
 College Park, Maryland 20740

Dear Sir or Madam:

In accordance with the requirement of Section 403 (r) (6) of the Federal Food, Drug and Cosmetic Act, and Rule CFR 101.93, we are hereby to notify FDA that Jarrow Formulas' **Jarro-Dophilus EPS™** product bears the following statements:

1. Jarrow Formulas®, Inc., 1824 S. Robertson Blvd., Los Angeles, CA 90035-4317
www.jarrow.com

2. **Statements*:**

- For intestinal and immune health
- *Bifidobacteria longum BB536 (morinaga strain)* has been shown to colonize, stimulate immune response and suppress intestinal pathogens. *L.rhamnosus R0011* is a unique, high producer of polysaccharides, which facilitate colonization and stimulate intestinal immune response. *Lactococcus and Pediococcus* help reduce spoilage caused by undesirable bacteria in cultured dairy products

*** These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.**

I certify that the information contained in the notice is complete and accurate, and that Jarrow Formulas has substantiation that the statement is truthful and not misleading.

Sincerely

Peilin Guo, MS, RD
 Dir. Functional Foods & Clinical Research
 Jarrow Formulas, Inc.
 Ph: 310-204-6936
 Fax: 310-736-3174
 e-mail: peilin@jarrow.com

Sid Shastri, CCN
 VP-Product Development

975 0162

LET

12262

84713